Tag Archives | Jubilant Organosys

More changes at Jubilant?

Jubilant Organosys appears to be taking one more step in transforming itself into a pharmaceutical company. The company is looking at selling its industrial and performance products division and expects to realise Rs3.0-3.5bn from the sale, says this report in today’s Economic Times. There was no official confirmation on this from the company. The division, […]

Continue Reading

Pharma still keen on M&As

The Indian pharmaceutical sector is keeping the M&A fire burning with six deals concluded last month, up from eight in the January-March period. The list includes Jubilant Organosys’ $255m acquisition of US-based DRAXIS Health and the $218m buyout of Dabur Pharma by Fresenius Kabi. Indian companies are expected to continue scouting for overseas assets although […]

Continue Reading
world%20crams.JPG

Testing times for CRAMS

Business is booming in India’s custom research and manufacturing services (CRAMS) industry thanks to the country’s strong process chemistry skills, low operational costs and the availability of a skilled workforce. Frost & Sullivan values the Indian CRAMS market at $890m, and expects it to expand by 40% in 2008. It estimates the market for outsourcing […]

Continue Reading

CRAMS: still going strong

Indian companies in the contract research and manufacturing services (CRAMS) domain appear to be doing well as is reflected in the stock market performance of these companies. The list includes Divi’s Laboratories, Dishman Pharmaceuticals & Chemicals, Nicholas Piramal, Shasun Chemicals & Drugs, and Jubilant Organosys This report in today’s Economic Times highlights that CRAMS companies’ […]

Continue Reading

Jubilant CRAMS another acquisition

Jubilant Organosys $123m acquisition of US-based Hollister-Stier Labs further consolidates is position in the global custom research and manufacturing (CRAMs) business. Interestingly, Jubilant will not be moving projects to India following the acquisition. In an interview with CNBC, Hari Bhartia, Jubilant’s managing director, says the company will be looking at expanding the Hollister-Stier facility and […]

Continue Reading

Indian chemicals score on CRAMS

Jubiliant Organosys’ announcement that it has clinched deals worth $60m from global life science majors reinforces India’s growing strength in the custom research and manufacturing services (CRAMS) business. Rising competition and research costs are supporting the CRAMS outsourcing wave and beneficiaries include Shasun Chemicals, Nicholas Piramal, Divis Lab and Dishman Pharma. A report in the […]

Continue Reading